What is the official website of Chiesi Group ?

The official website of Chiesi Group is https://http://www.chiesi.com.

What is Chiesi Group's cybersecurity risk score?

Chiesi Group has an AI-generated cybersecurity risk score of 775 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Chiesi Group experienced?

According to Rankiteo, Chiesi Group currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Chiesi Group been affected by any supply chain cyber incidents ?

According to Rankiteo, Chiesi Group has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Chiesi Group have SOC 2 Type 1 certification ?

According to Rankiteo, Chiesi Group is not certified under SOC 2 Type 1.

Does Chiesi Group have SOC 2 Type 2 certification ?

According to Rankiteo, Chiesi Group does not hold a SOC 2 Type 2 certification.

Does Chiesi Group comply with GDPR ?

According to Rankiteo, Chiesi Group is not listed as GDPR compliant.

Does Chiesi Group have PCI DSS certification ?

According to Rankiteo, Chiesi Group does not currently maintain PCI DSS compliance.

Does Chiesi Group comply with HIPAA ?

According to Rankiteo, Chiesi Group is not compliant with HIPAA regulations.

Does Chiesi Group have ISO 27001 certification ?

According to Rankiteo,Chiesi Group is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Chiesi Group operate in ?

Chiesi Group operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Chiesi Group have ?

Chiesi Group employs approximately 5,996 people worldwide.

Does Chiesi Group own any subsidiaries ?

Chiesi Group presently has no subsidiaries across any sectors.

How many LinkedIn followers does Chiesi Group have ?

Chiesi Group's official LinkedIn profile has approximately 273,088 followers.

What is the NAICS classification code for Chiesi Group ?

Chiesi Group is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Chiesi Group have a Crunchbase profile ?

No, Chiesi Group does not have a profile on Crunchbase.

Does Chiesi Group have a LinkedIn profile ?

Yes, Chiesi Group maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/chiesi-group.

How many cybersecurity incidents has Chiesi Group experienced ?

As of August 14, 2026, Rankiteo reports that Chiesi Group has not experienced any cybersecurity incidents.

How many peer or competitor companies does Chiesi Group have ?

Chiesi Group has an estimated 5,727 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Chiesi Group

Boost Score +25 with badge (5 left)

775

/1000

Fair

800

/1000

Good

Chiesi Group Vendor Cyber Rating & Cyber Score

chiesi.com

Add Your Compliance Badge

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG)

Chiesi Group A.I CyberSecurity Scoring

Scoring History

Chiesi Group

Chiesi Group CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Chiesi Group Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Chiesi Group

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Chiesi Group in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Chiesi Group in 2026.

Incident Types Chiesi Group vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Chiesi Group in 2026.

Incident History - Chiesi Group (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Chiesi Group Subsidiaries

Parent Company

Chiesi Group

Pharmaceutical Manufacturing

Website: https://http://www.chiesi.com

Company Size: 5,996

No subsidiary data available for this company.

Loading…

Chiesi Group Similar Companies

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Loading…

NEWS

Chiesi Group CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 22, 2025 08:00 AM

Chiesi USA Data Breach Exposes SSNs & Medical Info

Chiesi USA, Inc., a specialty pharmaceutical company headquartered in Cary, North Carolina, recently reported a significant data breach...

Read Article

November 12, 2025 08:00 AM

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada...

Read Article

October 08, 2025 07:00 AM

Arthrosi Therapies' $153 million for gout, Tokio Marine's M&A plans and Plug Power's new CEO

Venture Capital. Arthrosi Therapeutics, a San Diego-based gout treatment developer, raised a $153m Series E. Prime Eight Capital Limited...

Read Article

October 07, 2025 07:00 AM

Chiesi Group partners Arbor on gene editing programmes

Chiesi Group and Arbor have formed an exclusive partnership and licensing deal for the latter's investigational gene editing medicine.

Read Article

October 06, 2025 07:00 AM

Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programmes

Exclusive collaboration and license agreement for the development and global commercialisation of Arbor's clinical-stage gene editing...

Read Article

October 01, 2025 03:40 PM

How the Chiesi Group Is Closing Health Disparities

Explore how BCG experts helped reduce health disparities by eliminating barriers and improving care access for patients in low- and middle-income countries.

Read Article

June 05, 2025 07:00 AM

Italy's Chiesi Group plans acquisitions to boost sales to 6 billion euros by 2030

PARMA, Italy June 5 (Reuters) - Italy's Chiesi Group is aiming to significantly increase the number of patients it treats from around 10...

Read Article

January 03, 2025 08:00 AM

Inside the journey of Giuseppe Accogli: From med-tech veteran to Chiesi Group CEO

Explore how Giuseppe Accogli, CEO of Chiesi Group, drives global expansion, innovation, and sustainability in the pharmaceutical industry.

Read Article

December 20, 2024 08:00 AM

Chiesi earns EcoVadis Platinum Medal for the second year running

Chiesi Group is celebrating its second consecutive award of the prestigious EcoVadis Platinum Medal. Read more here.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-19756

SUMMARY

A vulnerability has been found in Dromara lamp-cloud up to 5.10.0. This affects an unknown part of the file DefGenProjectController.java of the component Code Generator. Such manipulation of the argument outputDir/parent/projectPrefix leads to path traversal. It is possible to launch the attack remotely. The exploit has been disclosed to the public and may be used. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-08-13

Updated

Date2026-08-13

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-19753

SUMMARY

A vulnerability was detected in Model Context Protocol mcp-rdf-explorer 1.0.0. Affected is the function explore_url of the file src/mcp-rdf-explorer/server.py of the component MCP Server. Performing a manipulation of the argument url results in server-side request forgery. The attack may be initiated remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-13

Updated

Date2026-08-13

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-73843

SUMMARY

OpenChoreo is a complete, open-source developer platform for Kubernetes. Prior to 1.0.2 and 1.1.2, internal/cluster-gateway/server.go served caller-facing management APIs on the externally reachable agent listener without authentication, allowing network-reachable attackers to invoke /api/proxy/ and /api/exec/ operations, proxy the data-plane Kubernetes API, and execute commands in workload pods in multi-cluster deployments. This issue is fixed in versions 1.0.2 and 1.1.2.

Published

Date2026-08-13

Updated

Date2026-08-13

RISK INFORMATION (Score: 9.6)

cvss3

Base Score: 9.6

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

Impact Score

Exploitability

2.8

REFERENCES

CVE-2026-73842

SUMMARY

OpenChoreo is a complete, open-source developer platform for Kubernetes. Prior to 1.0.3, 1.1.3, and 1.2.0-rc.2, internal/cluster-gateway/server.go exposed /api/proxy/, /api/exec/, and /api/wirelogs/ on an internal listener without requiring a client certificate or token, allowing any network-reachable caller to read tenant Kubernetes Secrets, mutate workloads, and execute commands across connected data planes. This issue is fixed in versions 1.0.3, 1.1.3, and 1.2.0-rc.2.

Published

Date2026-08-13

Updated

Date2026-08-13

RISK INFORMATION (Score: 9)

cvss3

Base Score: 9.0

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

Impact Score

Exploitability

2.3

REFERENCES

CVE-2026-73841

SUMMARY

OpenChoreo is a complete, open-source developer platform for Kubernetes. From 1.2.0-rc.1 until 1.2.0, internal/openchoreo-api/api/handlers/exec.go and internal/openchoreo-api/api/handlers/wirelogs.go authorize component:exec and wirelogs:view using the caller-supplied project query parameter instead of comp.Spec.Owner.ProjectName, allowing a user with a project-scoped grant to execute commands in and read wirelogs from components owned by other projects in the same namespace. This vulnerability is fixed in 1.2.0.

Published

Date2026-08-13

Updated

Date2026-08-13

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://github.com/openchoreo/openchoreo/security/advisories/GHSA-52gf-6rpq-fgmx

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…